SCHEMBL4265168

SCHEMBL4265168

Cc1cc(C)c(S(=O)(=O)N(C(CCNCCCCNCCCN)(S(=O)(=O)c2c(C)cc(C)cc2C)S(=O)(=O)c2c(C)cc(C)cc2C)S(=O)(=O)c2c(C)cc(C)cc2C)c(C)c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 1/20 0.34
CA2 P00918 3/20 0.33
CA1 P00915 2/20 0.33
MMP1 P03956 1/20 0.33
MMP2 P08253 1/20 0.33
MMP9 P14780 1/20 0.33
MMP8 P22894 1/20 0.33
MMP13 P45452 1/20 0.33
PAOX Q6QHF9 1/20 0.32
CA12 O43570 2/20 0.31
F13A1 P00488 2/20 0.31
CYP1A2 P05177 2/20 0.31
ALOX15 P16050 2/20 0.31
CA4 P22748 2/20 0.31
CA6 P23280 2/20 0.31
CA5A P35218 2/20 0.31
THPO P40225 2/20 0.31
CA7 P43166 2/20 0.31
CA9 Q16790 2/20 0.31
CA14 Q9ULX7 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6249429 0.77 ALDH1A1 (0.35) CA2CA1PAOXCA12ALOX15
SCHEMBL5605132 0.75 ALDH1A1 (0.35) CA2CA1MMP1MMP2MMP9
SCHEMBL7511658 0.72 FABP4 (0.61) FABP4CA2CA1MMP1MMP2
SCHEMBL4258883 0.71 FABP4 (0.59) FABP4CA2CA1MMP1MMP2
SCHEMBL7517048 0.70 FABP4 (0.61) FABP4CA2CA1MMP1MMP2
SCHEMBL7940206 0.69 FABP4 (0.34) FABP4CA2CA1MMP1MMP2
Norspermidine SCHEMBL28331693 0.69 CA12 (0.57) CA2CA1PAOXCA12F13A1
SCHEMBL7511654 0.69 FABP4 (0.59) FABP4CA2CA1MMP1MMP2
SCHEMBL7937672 0.65 FABP4 (0.36) FABP4CA2CA1MMP1MMP2
SCHEMBL7517054 0.65 F2 (0.41) FABP4CA2CA1MMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9676798-B2 Cationic oligonucleotides, automated methods for preparing same and their uses CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2017-06-13 US disclosed
US-20160280728-A1 CATIONIC OLIGONUCLEOTIDES, AUTOMATED METHODS FOR PREPARING SAME AND THEIR USES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2016-09-29 US disclosed
US-9090648-B2 Cationic oligonucleotides, automated methods for preparing same and their uses CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2015-07-28 US disclosed
EP-1973927-B1 CATIONIC OLIGONUCLEOTIDES, AUTOMATED METHODS FOR PREPARING SAME AND THEIR USES CENTRE NAT RECH SCIENT (FR) 2013-08-14 EP disclosed
US-20090069262-A1 Cationic Oligonucleotides, Automated Methods for Preparing Same and Their Uses CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2009-03-12 US disclosed
EP-1973927-A2 CATIONIC OLIGONUCLEOTIDES, AUTOMATED METHODS FOR PREPARING SAME AND THEIR USES Centre National De La Recherche Scientifique-CNRS (FR) 2008-10-01 EP disclosed
WO-2007069092-A2 CATIONIC OLIGONUCLEOTIDES, AUTOMATED METHODS FOR PREPARING SAME AND THEIR USES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160280728-A1 CATIONIC OLIGONUCLEOTIDES, AUTOMATED METHODS FOR PREPARING SAME AND THEIR USES HNRNPH3, SRM, SNRPB2 FABP4 3620/4885CA2 4159/4885CA1 2637/4885
US-20090069262-A1 Cationic Oligonucleotides, Automated Methods for Preparing Same and Their Uses HNRNPH3, RNASEH1, SRM FABP4 3520/4885CA2 4271/4885CA1 2885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.